Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting now · Phase 1

Conditions studied: Hematologic Disease

In brief

This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use highly mismatched unrelated HLA mismatched donors. Ultimately, an unrelated human leukocyte antigen (HLA) mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of this group of patients and truly enter the era of "everyone has a donor" for allo HSCT.

Key facts

Study ID

NCT06809712

Run by

He Huang

People needed

29

Starts

2022-08-04

Expected to finish

2027-10-31

Last updated by the study team

2026-06-09

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (18-60 years old) with hematological malignancies and indications for hematopoietic stem cell transplantation;
• Non blood donors without human leukocyte antigen (HLA) high-resolution typing ≥ 9/10, or those who have difficulty finding non blood donors due to urgent medical conditions;
• No suitable HLA matching haploidentical donor available;
• There are suitable unrelated HLA mismatched (HLA high-resolution typing<9/10) donors;
• The subjects or their legal representatives shall sign an informed consent form before the start of the clinical study.

You may not qualify if…

• Patients with severe liver and kidney function (alanine aminotransferase>2.5 times the upper limit of normal, blood creatinine>1.5 times the upper limit of normal) and cardiopulmonary dysfunction (New York Heart Association (NYHA) III/IV heart function, ejection fraction<50%, severe obstructive or restrictive ventilation dysfunction);
• Merge active infections;
• Eastern Cooperative Oncology Group Performance Status (ECOG) score ≥ 2 points;
• Secondary tumors with merged activity;
• Severe central nervous system or mental illness leading to the inability to autonomously choose to enter or exit clinical trials;
• Combine other allo hematopoietic stem cell transplantation (HSCT) contraindications.

Where it is running

• The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.